...
首页> 外文期刊>Macromolecular bioscience >Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions
【24h】

Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions

机译:树突状含糖聚合物作为蛋白酶体抑制剂硼替佐米在磷酸钙骨水泥中的药物递送系统:骨溶骨病变局部治疗的第一步

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Establishment of drug delivery system (DDS) in bone substitute materials for local treatment of bone defects still requires ambitious solutions for a retarded drug release. We present two novel DDS, a weakly cationic dendritic glycopolymer and a cationic polyelectrolyte complex, composed of dendritic glycopolymer and cellulose sulfate, for the proteasome inhibitor bortezomib. Both DDS are able to induce short-term retarded release of bortezomib from calcium phosphate bone cement in comparison to a burst-release of the drug from bone cement alone. Different release parameters have been evaluated to get a first insight into the release mechanism from bone cements. In addition, biocompatibility of the calcium phosphate cement, modified with the new DDS was investigated using human mesenchymal stromal cells.
机译:在用于局部治疗骨缺损的骨替代材料中建立药物递送系统(DDS)仍然需要雄心勃勃的解决方案来延缓药物的释放。我们提出了两种新型的DDS,一种弱阳离子树突糖聚合物和一种阳离子聚电解质复合物,由树突糖聚合物和硫酸纤维素组成,用于蛋白酶体抑制剂硼替佐米。与仅从骨水泥中突然释放药物相比,两种DDS都能诱导硼替佐米从磷酸钙骨水泥中的短期延迟释放。已评估了不同的释放参数,以初步了解从骨水泥释放的机制。此外,使用人间充质基质细胞研究了用新型DDS改性的磷酸钙水泥的生物相容性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号